MTMarta Torres-Ferrus

Marta Torres-Ferrus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta Torres-Ferrus has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross‐sectional study

    by Laura Gómez‐Dabó, Rut Mas‐De‐Les‐Valls, Ane Murillo, Víctor J. Gallardo, Marta Torres‐Ferrús, Alicia Alpuente, Teresa Mateu, Eulàlia Giné‐Ciprés, Edoardo Caronna, Patricia Pozo‐Rosich

    Background and Objectives: Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. Methods: A cross‐sectional study was conducted including females aged 18–60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen‐only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross‐checked with medical records and phone interviews. Age‐ and size‐matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. Results: A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p ‐values > 0.05). Among females in the RS and regular menstrual cycles ( n = 78), menstrually‐related migraine was highly prevalent (67/78; 86%). In the RS group comparisons ( n = 109), no differences according to HT use in migraine characteristics or menstruation‐related symptoms were observed (all adjusted p ‐values > 0.05). Similarly, among females in the menopause transition ( n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p ‐values > 0.05). Conclusions: In this real‐world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually‐related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.

  • Open Access

    Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis

    by María Garcés‐Pellejero, Marta Torres‐Ferrús, Rut Mas‐De‐Les‐Valls, Edoardo Caronna, Alicia Alpuente, Eulalia Giné‐Ciprés, Patricia Pozo‐Rosich

    Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.

  • Open Access

    Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort

    by Edoardo Caronna, Rut Mas-De-Les-Valls, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves Castellanos, Javier A Membrilla, Gloria Vaghi, Joana Rodríguez-Montolio, Neus Fabregat Fabra, Francisco Sánchez Caballero, et al.

    Background: The International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs). Methods: This was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category–migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4–6 MMD); insufficient control (>6 MMD)–after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group. Results: Of the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0–55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3–28.0] and 15.0 [10.0–20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD. Conclusions: High standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control.


  • Open Access

    Brain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine

    by Joana Rosell-Mirmi, Edoardo Caronna, Víctor J. Gallardo, Deborah Pareto, Alicia Alpuente, Marta Torres-Ferrús, Eulalia Giné-Ciprés, ÀLex Rovira, Patricia Pozo-Rosich

    Structural neuroimaging findings in migraine remain heterogeneous, and the impact of preventive treatments such as erenumab and onabotulinumtoxinA (OnabotA


  • Open Access

    Multimodal serum and MRI signatures of neuroaxonal injury in high-frequency migraine

    by Víctor J. Gallardo, Edoardo Caronna, Joana Rosell-Mirmi, Laila Asskour, Deborah Pareto, Marta Torres-Ferrús, Alicia Alpuente, Eulàlia Giné-Ciprés, Nara Ikumi, ÀLex Rovira, et al.

    It remains unclear whether high-frequency migraine is associated with objective markers of possible neuroaxonal injury and potential expression of neurodeg


  • Open Access

    Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration

    by Eulalia Gine-Cipres, Marta Torres-Ferrus, Víctor J Gallardo, Alicia Alpuente Ruiz, Edoardo Caronna, Laura Gomez-Dabo, Patricia Pozo-Rosich

    Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.

  • Open Access

    2025 highlights from real world studies in migraine

    by Edoardo Caronna, Marta Torres-Ferrús

  • Open Access

    Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days

    by Rut Mas-De-Les-Valls, Laura Gómez-Dabó, Edoardo Caronna, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich

    Background: Data on the effectiveness of preventive treatments on menstrually-related migraine (MRM) is scarce. Our objective was to analyze the efficacy of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) and onabotulinumtoxinA (BTX-A) in the reduction of perimenstrual headache days (PHD) and perimenstrual migraine days (PMD) compared to non-perimenstrual headache days (non-PHD) and non-perimenstrual migraine days (non-PMD) per month in women with MRM. Methods: A retrospective study was conducted including females with menstruation and headache records, treated with either anti-CGRP mAbs or BTX-A. Patients completed e-Diary one month before and three months after preventive treatment. We collected clinical data and analyzed PHD/PMD and non-PHD/non-PMD before and after treatment. Additional analyses included PHD/PMD and non-PHD/non-PMD comparisons grouped by aura, episodic/chronic migraine, treatment and contraceptive intake. Results: We analyzed data from 113 females with a median (range) age of 39.0 (33.0–45.0) years. When combining patients treated with anti-CGRP mAbs or BTX-A, a median (range) of 2.0 (2.0–3.0) PHD/month (corresponding to 13.6% baseline monthly headache days (MHD)) and 13.0 (9.0–17.0) non-PHD/month pre-treatment was observed. From these, 2.0 (1.0–3.0) were PMD/month, and 7.0 (4.0–11.0) were non-PMD/month. After treatment, the median PHD/month was 2.0 (1.0–3.0) (corresponding to 16.67% of MHD) ( p = 0.085), and 8.0 (5.0–13.0) were non-PHD/month ( p < 0.001); from these, 1.0 (0.0–3.0) were PMD/month (proportion difference, p = 0.035) and 4.0 (2.0–7.0) were non-PMD (proportion difference, p < 0.001). When analyzing grouped by treatment, only patients treated with anti-CGRP experienced a reduction in PMD. No statistically significant differences in clinical factors (aura, migraine diagnosis, contraceptive intake) between PHD/non-PHD or PMD/non-PMD, either pre- or post-treatment. A higher probability risk of headache and migraine during the perimenstrual window was observed independently of the treatment received (odds ratio = 1.637, 95% confidence interval = 1.356–1.984, p < 0.001). Conclusions: Three-month treatment with anti-CGRP mAbs or BTX-A effectively reduced non-PHD and non-PMD but had limited effect on PHD/PMD because headache probability risk was higher during the perimenstrual window after treatment.


  • Top Cited Papers
    Open Access

    Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache

    by Patricia Pozo-Rosich, Nancy van Veelen, Edoardo Caronna, Gloria Vaghi, Marta Torres-Ferrus, Britt W.H. van der Arend, Peter J. Goadsby, Messoud Ashina, Shuu-Jiun Wang, Hans-Christoph Diener, et al.

    Real-world evidence studies are an important tool for investigating the effectiveness, safety and tolerability of treatments for headache disorders in clinical practice. These studies use data generated from routine clinical practice from a variety of sources and can help to identify unmet needs in headache care and guide new therapies, including populations not always included in randomized clinical trials of different ages, comorbidities, and concomitant stable treatments. Real-world evidence pertains to the clinical evidence surrounding the utilization, as well as the potential advantages or drawbacks of treatment, which is extracted through an analysis of real-world data. Real-world evidence studies can present unique challenges, including timing of data collection (prospective vs retrospective), data selection, data quality issues and potential biases (selection, confounding factors, etc.). The International Headache Society has developed these guidelines for optimizing the design and conduct of real-world evidence studies, and therefore the strength and reliability of their output.